Infectious Diseases Research

Below are current clinical trials.

259 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. A Study to Detect and Candida auris

   Rochester, Minn.

   The purpose of this study is to develop a test that can be used routinely to detect and identify Candida auris from surveillance skin swabs.

    

2. Acupuncture Therapy for COVID-Related Olfactory Loss

   Rochester, Minn.

   The objectives of this study are to describe the incidence of COVID-related olfactory loss, to compare the effectiveness of acupuncture, steroid rinses, and olfactory training versus steroid rinses and olfactory training in the treatment of COVID-related olfactory loss, and to recommend a treatment paradigm for patients with COVID-related olfactory loss.

    

3. Safety and Immune Response of the COVID 19 Vaccine in Patients with Inflammatory Bowel Disease

   Jacksonville, Fla.

   This will be a prospective study of patients with IBD at Mayo Clinic initially in Jacksonville with possible subsequent extension to other Mayo sites.  We will evaluate the immunogenicity of commercially available COVID-19 vaccines and compare vaccine response among the groups based on their immunosuppressive regimens.  We will divide the immunosuppressive regimens into presumed high vaccine responders Group A and presumed low vaccine responders Group B. We will also assess for adverse reactions to the vaccine and compare with the reported rates in the clinical trials that led to approval of these vaccines.

4. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 (enrollment by invitation only)

   Rochester, Minn.

   Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19.

   Phase 3: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19.

5. Presatovir In Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection Of The Upper Respiratory Tract

   Scottsdale/Phoenix, Ariz.

   This study will evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV upper respiratory tract infection (URTI), the effect of presatovir on development of lower respiratory tract complication, being free of any supplemental oxygen progression to respiratory failure, and pharmacokinetics (PK), safety, and tolerability of presatovir.

6. A Study Comparing The Effectiveness And Safety Of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma For The Treatment Of Severe Influenza A

   Rochester, Minn.

   The purpose of this study is to assess the effectiveness and safety of giving anti-influenza immune plasma, as an addition to standard of care antivirals, to patients hospitalized with severe influenza A infection.

7. Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin In Subjects With Chronic HCV With Advanced Liver Disease Or Post-Liver Transplant

   Jacksonville, Fla.

   The purpose of this study is to evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with chronic genotype 1 or 4 hepatitis C virus (HCV) infection. Participants will be randomized to receive 12 or 24 weeks of dosing with the LDV/SOF FDC tablet+ribavirin (RBV).

8. An Expanded Access Study Of Sofosbuvir Combined With Ribavirin And Either With Or Without Pegylated Interferon For Treating Aggressive Post-Transplant Hepatitis C

   Jacksonville, Fla.

   The purpose of this study, is to open expanded access at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Patients who have an aggressive, recurring hepatitis C infection following liver transplant, will be given sofosbuvir combined with ribavirin, and pegylated interferon may or may not be added at the discretion of the investigator.

9. A Study To Determine Late Outcomes And Immunological Responses In Children With/Without Multisystem Inflammatory Syndrome After SARS-CoV-2

   Rochester, Minn.

   The purpose of this study is to assess short- and long-term clinical outcomes and immune responses after SARS-CoV-2 infection and/or MIS-C in children (defined as individuals who have not yet reached their 21st birthday).  Participants will be identified through active recruitment measures within hospitals and through ambulatory and laboratory-based databases of SARS-CoV-2 positive children. 

10. Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients

    Rochester, Minn.

    This is a study of two different approaches for the prevention of CMV disease in liver transplant recipients. The primary purpose is to determine if Preemptive therapy is the same or better than Prophylaxis therapy for the prevention of CMV disease in CMV seronegative recipients that receive a CMV positive liver transplant. Patients meeting study criteria and who have provided informed consent will be randomized within 10 days of transplant to receive in an open label design, either antiviral prophylaxis with valganciclovir 900 mg orally once daily for 100 days or preemptive therapy (weekly monitoring for asymptomatic CMV viremia by plasma PCR) for 100 days with initiation of oral valganciclovir 900mg orally twice daily only at onset of CMV viremia and continued until plasma PCR is negative on two consecutive weekly PCR tests.